CBO Says Cost to Taxpayers of Covering GLP-1 Medications Would Outpace Savings from “Reducing Other Health Care Spending” In case you missed it, the Congressional Budget Office (CBO) recently predicted that covering GLP-1 weight loss drugs “at their current prices, would cost the federal government more than it would save from reducing other health care […]
Big Pharma Exec Downplays “Modest” Drug Pricing Solutions That CEO Previously Claimed Would Reduce R&D and Called “Gun to Your Head” Big Pharma can’t seem to keep its story straight. The pharmaceutical industry continues to accidentally debunk its own doom-and-gloom rhetoric insisting solutions to lower drug prices by holding brand name drug companies accountable will […]
Median Price Set by Brand Name Drug Makers on New Treatments Climbs to $300,000 In case you missed it, on Friday, Reuters released a new analysis which found that the median annual price among new drugs approved by the U.S. Food and Drug Administration (FDA) in 2023 reached $300,000. This number was 35 percent higher than the […]
GLP-1 Weight-Loss Leaders “Blow Past” Wall Street Projections in Q4 2023, Hike Prices on at Least 20 Brand Name Products in First Weeks of 2024 Big Pharma giants Eli Lilly and Novo Nordisk recently reported earnings that blew past Wall Street estimates for the fourth quarter of 2023. Both brand name companies have become leaders […]
More Big Pharma Giants Report Earnings That Top Wall Street Expectations While Continuing to Hike Prices on Dozens of Brand Name Drugs Merck, Bristol Myers Squibb, and AbbVie all recently reported earnings for the fourth quarter of 2023 that topped Wall Street analysts’ expectations after all three Big Pharma giants engaged in price hikes in […]
Patent Abuse Designed to Extend Monopolies, Block Competition and Keep Prices High Takes Center Stage at HELP Committee Hearing On Thursday, the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) held a hearing with the CEOs of three Big Pharma giants: Johnson & Johnson, Merck and Bristol Myers Squibb. During the hearing, lawmakers, […]
Big Pharma Giants Continue Q4 Earnings Besting Wall Street Expectations Pfizer and GlaxoSmithKline (GSK) are the latest Big Pharma giants to report Wall Street-besting earnings for the fourth quarter of 2023. Both companies topped analysts’ expectations after hiking prices on blockbuster products throughout the year. One key area for both companies was their recently launched […]
JAMA Analysis Finds Patents for Active Ingredients for Weight Loss Drugs Significantly Lower than for Other Prescription Drugs That Rely on Drug-Device Combinations A new analysis published in JAMA Network finds that the brand name drug makers marketing a new category of weight loss drugs, glucagon-like peptide 1 (GLP-1) receptor agonists, are increasingly utilizing device […]
Lawmakers and Experts Will Discuss Solutions to Hold Big Pharma Accountable for Anti-Competitive Tactics That Keep Drug Prices High Washington, D.C. – On Tuesday, February 6 at 10:00 AM, Campaign for Sustainable Rx Pricing (CSRxP) executive director Lauren Aronson will participate in a panel discussion with U.S. Senators Peter Welch (D-VT) and Amy Klobuchar (D-MN) on […]
Big Pharma Giant Kicks Off Q4 Earnings After Hiking Prices More Than 40 Times in 2023 This past week, brand name drug giant Johnson & Johnson kicked off the first round of Big Pharma earnings calls for the fourth quarter of 2023. The company surpassed Wall Street analysts’ earnings and profit expectations after hiking prices […]